Glenmark Life Sciences Limited has submitted a regulatory disclosure to BSE Ltd under SEBI Listing Obligations and Disclosure Requirements Regulation 30 regarding share acquisitions by its promoter group.
The promoter group acquired 13,200 equity shares from public shareholders on August 5, 2026, for an aggregate consideration of ₹14,43,744 at the prevailing market price of ₹109.37 per share.
Subsequently, on August 6, 2026, the promoter group acquired an additional 31,200 equity shares from public shareholders for an aggregate consideration of ₹35,22,840 at the prevailing market price of ₹112.91 per share.
The total acquisition comprises 44,400 equity shares with a combined value of ₹49,66,584.
Consequent to these acquisitions, the aggregate shareholding of the promoter and promoter group has increased from 73.71% to 73.89% of the total paid-up equity share capital of the company.
The company has confirmed that these acquisitions were carried out after ensuring compliance with the minimum public shareholding requirements as prescribed under SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.
The disclosure was signed by Shikha Sureka, Company Secretary and Compliance Officer of Glenmark Life Sciences Limited, and submitted to BSE Ltd on August 6, 2026.